Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole

Bor-Shyang Sheu, Wei-Lun Chang, Hsiu-Chi Cheng, Ai Wen Kao, Cheng-Chan Lu

研究成果: Article

35 引文 (Scopus)

摘要

AIMS: This study assessed the endoscopic healing rates of reflux esophagitis with Los Angeles grades C and D (RE-CD) using a 6-month esomeprazole and the demographic factors or genotypes of S-mephenytoin 4′-hydroxylase (CYP2C19) that correlated with the healing of RE-CD. METHODS: One hundred thirteen patients with RE-CD received esomeprazole 40 mg daily for 6 months and completed serial follow-ups regarding healing by endoscopies at the 1st month and the 6th month, respectively. In each patient, demographic factors, including body mass index (BMI), and the CYP2C19 genotypes were checked. RESULTS: The endoscopic healing rates of RE-CD were similar among patients with different genotypes of CYP2C19 at the 1st month and the 6th month, respectively (P > 0.05). A lower healing rate of RE-CD at the 1st month was independently related to a higher BMI > 25 kg/m2, coffee drinking, and the presence of hiatus hernia (P < 0.05), but not with the CYP2C19 genotypes. A higher BMI > 25 kg/m2 independently had a 2.32-fold decrease of the healing of RE-CD (P < 0.001), but a net decrease of BMI > 1.5 kg/m2 independently had a 3.65-fold increase of the healing of RE-CD at the 6th month (P = 0.014). CONCLUSIONS: Esomeprazole 40 mg daily can be effective for RE-CD patients with different CYP2C19 genotypes. BMI > 25 kg/m2 is an independent risk factor to determine the healing of RE-CD by esomeprazole. Reducing BMI > 1.5 kg/m2, especially for those with an initial BMI > 25 kg/m2, could be promising to improve the healing of RE-CD by esomeprazole.

原文English
頁(從 - 到)2209-2214
頁數6
期刊American Journal of Gastroenterology
103
發行號9
DOIs
出版狀態Published - 2008 九月 1

指紋

Esomeprazole
Peptic Esophagitis
Los Angeles
Body Mass Index
Genotype
Demography
Hiatal Hernia
Coffee
Endoscopy
Drinking
Cytochrome P-450 CYP2C19

All Science Journal Classification (ASJC) codes

  • Gastroenterology

引用此文

@article{b15fbeea49944565b02e5dbcd59337be,
title = "Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole",
abstract = "AIMS: This study assessed the endoscopic healing rates of reflux esophagitis with Los Angeles grades C and D (RE-CD) using a 6-month esomeprazole and the demographic factors or genotypes of S-mephenytoin 4′-hydroxylase (CYP2C19) that correlated with the healing of RE-CD. METHODS: One hundred thirteen patients with RE-CD received esomeprazole 40 mg daily for 6 months and completed serial follow-ups regarding healing by endoscopies at the 1st month and the 6th month, respectively. In each patient, demographic factors, including body mass index (BMI), and the CYP2C19 genotypes were checked. RESULTS: The endoscopic healing rates of RE-CD were similar among patients with different genotypes of CYP2C19 at the 1st month and the 6th month, respectively (P > 0.05). A lower healing rate of RE-CD at the 1st month was independently related to a higher BMI > 25 kg/m2, coffee drinking, and the presence of hiatus hernia (P < 0.05), but not with the CYP2C19 genotypes. A higher BMI > 25 kg/m2 independently had a 2.32-fold decrease of the healing of RE-CD (P < 0.001), but a net decrease of BMI > 1.5 kg/m2 independently had a 3.65-fold increase of the healing of RE-CD at the 6th month (P = 0.014). CONCLUSIONS: Esomeprazole 40 mg daily can be effective for RE-CD patients with different CYP2C19 genotypes. BMI > 25 kg/m2 is an independent risk factor to determine the healing of RE-CD by esomeprazole. Reducing BMI > 1.5 kg/m2, especially for those with an initial BMI > 25 kg/m2, could be promising to improve the healing of RE-CD by esomeprazole.",
author = "Bor-Shyang Sheu and Wei-Lun Chang and Hsiu-Chi Cheng and Kao, {Ai Wen} and Cheng-Chan Lu",
year = "2008",
month = "9",
day = "1",
doi = "10.1111/j.1572-0241.2008.01979.x",
language = "English",
volume = "103",
pages = "2209--2214",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole

AU - Sheu, Bor-Shyang

AU - Chang, Wei-Lun

AU - Cheng, Hsiu-Chi

AU - Kao, Ai Wen

AU - Lu, Cheng-Chan

PY - 2008/9/1

Y1 - 2008/9/1

N2 - AIMS: This study assessed the endoscopic healing rates of reflux esophagitis with Los Angeles grades C and D (RE-CD) using a 6-month esomeprazole and the demographic factors or genotypes of S-mephenytoin 4′-hydroxylase (CYP2C19) that correlated with the healing of RE-CD. METHODS: One hundred thirteen patients with RE-CD received esomeprazole 40 mg daily for 6 months and completed serial follow-ups regarding healing by endoscopies at the 1st month and the 6th month, respectively. In each patient, demographic factors, including body mass index (BMI), and the CYP2C19 genotypes were checked. RESULTS: The endoscopic healing rates of RE-CD were similar among patients with different genotypes of CYP2C19 at the 1st month and the 6th month, respectively (P > 0.05). A lower healing rate of RE-CD at the 1st month was independently related to a higher BMI > 25 kg/m2, coffee drinking, and the presence of hiatus hernia (P < 0.05), but not with the CYP2C19 genotypes. A higher BMI > 25 kg/m2 independently had a 2.32-fold decrease of the healing of RE-CD (P < 0.001), but a net decrease of BMI > 1.5 kg/m2 independently had a 3.65-fold increase of the healing of RE-CD at the 6th month (P = 0.014). CONCLUSIONS: Esomeprazole 40 mg daily can be effective for RE-CD patients with different CYP2C19 genotypes. BMI > 25 kg/m2 is an independent risk factor to determine the healing of RE-CD by esomeprazole. Reducing BMI > 1.5 kg/m2, especially for those with an initial BMI > 25 kg/m2, could be promising to improve the healing of RE-CD by esomeprazole.

AB - AIMS: This study assessed the endoscopic healing rates of reflux esophagitis with Los Angeles grades C and D (RE-CD) using a 6-month esomeprazole and the demographic factors or genotypes of S-mephenytoin 4′-hydroxylase (CYP2C19) that correlated with the healing of RE-CD. METHODS: One hundred thirteen patients with RE-CD received esomeprazole 40 mg daily for 6 months and completed serial follow-ups regarding healing by endoscopies at the 1st month and the 6th month, respectively. In each patient, demographic factors, including body mass index (BMI), and the CYP2C19 genotypes were checked. RESULTS: The endoscopic healing rates of RE-CD were similar among patients with different genotypes of CYP2C19 at the 1st month and the 6th month, respectively (P > 0.05). A lower healing rate of RE-CD at the 1st month was independently related to a higher BMI > 25 kg/m2, coffee drinking, and the presence of hiatus hernia (P < 0.05), but not with the CYP2C19 genotypes. A higher BMI > 25 kg/m2 independently had a 2.32-fold decrease of the healing of RE-CD (P < 0.001), but a net decrease of BMI > 1.5 kg/m2 independently had a 3.65-fold increase of the healing of RE-CD at the 6th month (P = 0.014). CONCLUSIONS: Esomeprazole 40 mg daily can be effective for RE-CD patients with different CYP2C19 genotypes. BMI > 25 kg/m2 is an independent risk factor to determine the healing of RE-CD by esomeprazole. Reducing BMI > 1.5 kg/m2, especially for those with an initial BMI > 25 kg/m2, could be promising to improve the healing of RE-CD by esomeprazole.

UR - http://www.scopus.com/inward/record.url?scp=50649085480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649085480&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2008.01979.x

DO - 10.1111/j.1572-0241.2008.01979.x

M3 - Article

C2 - 18702650

AN - SCOPUS:50649085480

VL - 103

SP - 2209

EP - 2214

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -